DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • United Kingdom
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
AGY logo

Allergy Therapeutics plc Stock Price

AIM:AGY Community·UK£300.8m Market Cap
  • 0 Narratives written by author
  • 0 Comments on narratives written by author
  • 1 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

AGY Share Price Performance

UK£0.048
-0.04 (-42.77%)
​
UK£0.048
-0.04 (-42.77%)
​
Price UK£0.048
Tue, 22 Sep 26
Share Pricen/a

AGY Community Narratives

There are no narratives available yet.
Create Narrative
There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Slight risk with imperfect balance sheet.

4 Risks
0 Rewards
View Full Analysis

Allergy Therapeutics plc Key Details

UK£57.3m

Revenue

UK£27.4m

Cost of Revenue

UK£29.9m

Gross Profit

UK£78.1m

Other Expenses

-UK£48.2m

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-0.0076
52.22%
-84.08%
474.5%
View Full Analysis

About AGY

Founded
1998
Employees
584
CEO
Manuel Llobet
WebsiteView website
www.allergytherapeutics.com

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also develops Grass MATA MPL, a subcutaneous allergen-specific immunotherapy candidate that aims to address the cause of symptoms of allergic rhinoconjunctivitis due to grass pollen; and VLP Peanut, a short-course peanut allergy vaccine. Allergy Therapeutics plc was founded in 1998 and is headquartered in Worthing, the United Kingdom.

Recent AGY News & Updates

Recent updates

No updates

Allergy Therapeutics plc Competitors

OXB logo

Oxford Biomedica

Symbol: LSE:OXB
Market cap: UK£562.8m
AVCT logo

Avacta Group

Symbol: AIM:AVCT
Market cap: UK£365.4m
PRTC logo

PureTech Health

Symbol: LSE:PRTC
Market cap: UK£296.7m
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide